Medical devices

Medical devices

Medical devices

Until the application of a new regulatory framework for the EU beginning from 26 May 2021, the regulatory framework in the EU for medical devices, active implantable medical devices (AIMDs), and in vitro diagnostic medical devices (IVDs) consisted of:

•
Directive 93/42/EEC on medical devices
•
Directive 90/385/EEC on active implantable medical devices
•
Directive 98/79/EC on in vitro diagnostic medical devices

These MD Directives remain relevant to ‘legacy’ devices and those that were placed on the market before applicable deadlines for certain devices to transition to the new EU regulations. However, all devices must comply with certain increased obligations of compliance under the new EU medical devices regulatory regime. See Practice Note: An introduction to the regulation of medical devices—EU Directives regime.

In the UK, the MD Directives have been implemented via the Medical Devices Regulations 2002 (MDR 2002), SI 2002/618, which were issued under the Consumer Protection Act 1987. The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK competent authority responsible for supervision of medical device regulation. The end of the Brexit transition period

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

PAGB publishes report on AI applications in consumer healthcare advertising

The Proprietary Association of Great Britain (PAGB) has published a report examining artificial intelligence applications in consumer healthcare advertising following engagement with members, regulators, industry experts and international trade associations. The report identifies current AI usage in creative development, claim generation and compliance monitoring, while highlighting concerns regarding accuracy, confidentiality, liability and the requirement for human oversight. PAGB Deputy CEO Laura Kelly stated the organisation will continue examining AI integration opportunities while assessing risks to ensure adopted tools deliver value for members. The trade association represents manufacturers of branded over-the-counter medicines, self-care medical devices and food supplements in the UK.

MHRA publishes health institution exemption call for evidence outcome

The Medicines and Healthcare products Regulatory Agency (MHRA) has published the outcome of its call for evidence on health institution exemptions within the medical devices regulatory framework. The survey, which ran from 1 August to 15 September 2025, gathered insights from health institutions across Great Britain on their experience of the exemption, sometimes referred to as in-house manufacturing exemption. The MHRA aims to refine the policy to enable exempted devices to be used beyond health institutions, strengthen safety measures through enhanced post-market surveillance, and support delivery of care closer to communities. The outcome will inform subsequent consultations, guidance updates, and regulatory changes planned for the coming year as part of the Medical Devices Regulatory Reform roadmap.

MHRA publishes research on awareness and harm reporting for DMHT users

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a report presenting findings from its research which explored how current and potential users of digital mental health technologies (DMHT) and intermediaries understood the potential for harm posed by DMHT, how they might recognise harm to themselves or others and how they could be encouraged and facilitated to report it via the MHRA Yellow Card Scheme. The study found that although many participants had experience with mental health apps, few recognised the term DMHT or perceived significant risks, though some concerns were raised about excessive screen time, financial exclusion, use of AI, self-treatment, misdiagnosis and addiction. Awareness of the Yellow Card scheme was low, and most users were unlikely to report harms unless guided by healthcare professionals. Participants supported embedding simple reporting tools within apps and increasing awareness through NHS channels.

Life Sciences weekly highlights—20 November 2025

This week's edition of Life Sciences weekly highlights includes analysis on the decision of the UK Court of Appeal decision clarifying the approach of UK courts to confidentiality in patent litigation. Also included, is news that the European Commission proposed a new Digital Package aimed at simplifying EU technology and data rules across Member States, the IP guidance for the NHS has been revised to streamline processes and encourage innovation, the DSIT announced a significant funding package to support a series of pioneering life sciences initiatives, the EFPIA and Vaccines Europe (VE) set out several priorities for the EU Biotech Act in its response to the public consultation, the MHRA announced its pilot programme offering clinical investigation application fee waivers to micro and small UK enterprises developing innovative medical devices, the MHRA also launched a consultation on adopting draft ICH guideline Q3E for Extractables and Leachables to establish a holistic framework for the assessment and control of leachable impurities, and European Notified Bodies (Team-NB) adopted a position paper and template agreement governing the transfer of a Medical Devices Regulation (MDR) formal application, among other stories.